Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health Administration

BACKGROUND: Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in patients with non-valvular atrial fibrillation (NVAF). It does not require routine monitoring with laboratory testing which may have an adverse impact on adherence. We aimed to describe adherence to dabigatra...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am Heart J
Autors principals: Shore, Supriya, Carey, Evan P., Turakhia, Mintu P., Jackevicius, Cynthia A., Cunningham, Fran, Pilote, Louise, Bradley, Steven M., Maddox, Thomas M., Grunwald, Gary K., Barón, Anna E., Rumsfeld, John S., Varosy, Paul D., Schneider, Preston M., Marzec, Lucas N., Ho, P. Michael
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5381802/
https://ncbi.nlm.nih.gov/pubmed/24890529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ahj.2014.03.023
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars